基于肿瘤免疫微环境的肝癌分子分型研究进展

doi:10.11904/j.issn.1002-3070.2021.06.014

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (6): 557-561.doi: 10.11904/j.issn.1002-3070.2021.06.014

基于肿瘤免疫微环境的肝癌分子分型研究进展

刘菲综述, 隋红审校

哈尔滨医科大学附属肿瘤医院(哈尔滨 150081)

收稿日期:2021-03-09 修回日期:2021-05-06 出版日期:2021-12-28 发布日期:2021-12-17
通讯作者: 隋红,E-mail:doctorsui2003@126.com
作者简介:刘菲,女,(1997-),硕士研究生,从事消化道肿瘤的研究。
基金资助:
哈尔滨医科大学海燕科研基金(编号:JJZD2019-08)

Research progress in molecular classification of liver cancer based on tumor immunological microenvironment

LIU Fei, SUI Hong

Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2021-03-09 Revised:2021-05-06 Online:2021-12-28 Published:2021-12-17

摘要/Abstract

摘要： 免疫治疗改善了肝癌整体治疗策略,其特有的免疫异质特征和对免疫微环境的高度耐受使免疫治疗进入瓶颈阶段,因此对于可能受益于免疫检查点治疗的患者来说,划分肝癌分子分型是必要的。随着二代测序技术的进步,科学家根据浸润性免疫细胞丰度、免疫检查点表达水平、多组学数据、免疫抑制互斥机制及肿瘤微环境异质性等各个层面进行分子分型探索,不仅将肝癌特定生物学、分子和临床病理特征与肿瘤微环境关联,而且显示出与转录组分子分型的重叠之处,有利于未来肝癌的诊断、治疗方式选择和预测临床结局,推动精确的肝癌个体化免疫治疗。

关键词: 肝细胞癌, 肿瘤免疫微环境, 分子分型, 免疫检查点抑制剂

Abstract: Immunotherapy improves the overall treatment strategy of liver cancer. Its unique immune heterogeneity and high tolerance to immune microenvironment make immunotherapy enter the bottleneck stage.Therefore,it is necessary to classify molecular classifications of liver cancer patients who may benefit from immune checkpoint therapy.With the progress of next-generation sequencing technology,scientists have explored molecular classifications based on the abundance of infiltrating immune cells,the expression of immune checkpoints,multi-omics data,mutually exclusive mechanisms for immunosuppression and the heterogeneity of tumor microenvironment.It is not only the specific biological,molecular and clinicopathological characteristics of liver cancer associated with the tumor microenvironment,but it also shows the overlap with the molecular classifications of the transcriptome.It is beneficial to the diagnosis of liver cancer,the choice of treatment methods and the prediction of clinical outcomes,and promotes accurate individualized immunotherapy for liver cancer.

Key words: Hepatocellular carcinoma, Tumor immunological microenvironment, Molecular classifications, Immune checkpoint inhibitor

中图分类号:

R735.7

刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.

LIU Fei, SUI Hong. Research progress in molecular classification of liver cancer based on tumor immunological microenvironment[J]. Journal of Practical Oncology, 2021, 35(6): 557-561.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.06.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I6/557

参考文献

1 Galle PR,Forner A,Llovet JM,et al.EASL clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2018,69(1):182-236.
2 Nishida N,Kudo M.Immune checkpoint blockade for the treatment of human hepatocellular carcinoma[J].Hepatol Res,2018,48(8):622-634.
3 Chew V,Lai L,Pan L,et al.Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses[J].Proc Natl Acad Sci U S A,2017,114(29):5900-5909.
4 徐洋,秦琪,赵红,等.肿瘤微环境异质性的研究进展[J].实用肿瘤学杂志,2017,31(3):258-261.
5 Lee JS,Chu IS,Heo J,et al.Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling[J].Hepatology,2004,40(3):667-676.
6 Chiang DY,Villanueva A,Hoshida Y,et al.Focal gains of VEGFA and molecular classification of hepatocellular carcinoma[J].Cancer Res,2008,68(16):6779-6788.
7 Hoshida Y,Nijman SM,Kobayashi M,et al.Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma[J].Cancer Res,2009,69(18):7385-7392.
8 Ahn SM,Haq F,Park I,et al.The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma[J].BMC Cancer,2018,18(1):571.
9 Maman S,Witz IP.A history of exploring cancer in context[J].Nat Rev Cancer,2018,18(6):359-376.
10 Sia D,Jiao Y,Martinez-Quetglas I,et al.Identification of an immune-specific class of hepatocellular carcinoma,based on molecular features[J].Gastroenterology,2017,153(3):812-826.
11 Ally A,Balasundaram M,Carlsen R,et al.Comprehensive and integrative genomic characterization of hepatocellular carcinoma[J].Cell,2017,169(7):1327-1341.
12 Shimada S,Mogushi K,Akiyama Y,et al.Comprehensive molecular and immunological characterization of hepatocellular carcinoma[J].EBioMedicine,2019,40:457-470.
13 Kurebayashi Y,Ojima H,Tsujikawa H,et al.Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification[J].Hepatology,2018,68(3):1025-1041.
14 Tsujikawa H,Masugi Y,Yamazaki K,et al.Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness[J].Hum Pathol,2016,50:24-33.
15 Kim HD,Song GW,Park S,et al.Association between expression level of PD1 by tumor-Infiltrating CD8(+)T cells and features of hepatocellular carcinoma[J].Gastroenterology,2018,155(6):1936-1950.
16 Zhang Q,Lou Y,Yang J,et al.Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas[J].Gut,2019,68(11):2019-2031.
17 Geiger R,Rieckmann JC,Wolf T,et al.L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity[J].Cell,2016,167(3):829-842.
18 Fujita M,Yamaguchi R,Hasegawa T,et al.Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations[J].EBio Medicine,2020,53:102659.
19 Leman JKH,Sandford SK,Rhodes JL,et al.Multiparametric analysis of colorectal cancer immune responses[J].World J Gastroenterol,2018,24(27):2995-3005.
20 Taylor NA,Vick SC,Iglesia MD,et al.Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer[J].J Clin Invest,2017,127(9):3472-3483.
21 Vitale I,Manic G,Coussens LM,et al.Macrophages and metabolism in the tumor microenvironment[J].Cell Metab,2019,30(1):36-50.
22 Zheng C,Zheng L,Yoo JK,et al.Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing[J].Cell,2017,169(7):1342-1356.
23 Liu Z,Zhang Y,Shi C,et al.A novel immune classification reveals distinct immune escape mechanism and genomic alterations:implications for immunotherapy in hepatocellular carcinoma[J].J Transl Med,2021,19(1):5.
24 Garcia J,Hurwitz HI,Sandler AB,et al.Bevacizumab(Avastin(R))in cancer treatment:a review of 15 years of clinical experience and future outlook[J].Cancer Treat Rev,2020,86:102017.
25 Shen J,Ju Z,Zhao W,et al.ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade[J].Nat Med,2018,24(5):556-562.
26 Jiang H,Hegde S,Knolhoff BL,et al.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy[J].Nat Med,2016,22(8):851-860.
27 Gao Q,Zhu H,Dong L,et al.Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J].Cell,2019,179(2):561-577.
28 Ribas A,Dummer R,Puzanov I,et al.Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy[J].Cell,2017,170(6):1109-1119.
29 Lin Z,Lu D,Wei X,et al.Heterogeneous responses in hepatocellular carcinoma:the achilles heel of immune checkpoint inhibitors[J].Am J Cancer Res,2020,10(4):1085-1102.

[1]	于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.
[2]	纪雷, 纪道林, 鲍冬冬, 谭刚. lncRNA在肝细胞癌索拉非尼耐药中的最新研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 562-567.
[3]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[4]	赵浩然, 李满, 张玉宝. 肝细胞癌相关RNA结合蛋白研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 576-579.
[5]	贺玲, 姚克铖. 糖基磷脂酰肌醇转酰胺酶与肝癌[J]. 实用肿瘤学杂志, 2021, 35(5): 458-461.
[6]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[7]	刘克, 王胜林. 乳腺浸润性导管癌的X光影像与分子分型及其组织学分级的相关性研究[J]. 实用肿瘤学杂志, 2021, 35(2): 148-153.
[8]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[9]	石琳娜, 隋红. 原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J]. 实用肿瘤学杂志, 2020, 34(6): 560-564.
[10]	李慧, 庞达. 三阳型乳腺癌的临床病理学特点及辅助治疗[J]. 实用肿瘤学杂志, 2020, 34(3): 262-265.
[11]	师镘茹, 鄂明艳. 放疗延迟对乳腺癌不同分子亚型患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 431-435.
[12]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
[13]	姚洋张艳桥. 胃癌免疫检查点抑制剂作用机制及最新研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 371-375.
[14]	赵凌云, 齐鲁楠, 游雪梅审校. 热休克蛋白70在肝细胞癌中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 528-532.
[15]	曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.

基于肿瘤免疫微环境的肝癌分子分型研究进展

Research progress in molecular classification of liver cancer based on tumor immunological microenvironment

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价